Marketing: Page 82
-
Sanofi/Regeneron's opening move on PCSK9 marketing: 'Cholesterol Counts' campaign
Praluent (alirocumab) is being hailed as a "next-generation" cholesterol treatment with multi-billion dollar sales potential.
By Nicole Gray • Dec. 17, 2014 -
How Teva's CEO is preparing for a 2015 of patent expirations
While speaking to analysts in NY, Teva CEO Erez Vigodman outlined the company's growth strategy for next year.
By Nicole Gray • Dec. 16, 2014 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
Deep Dive
The 11 biggest drug launches to watch in 2015
A new report predicts that candidates from Sanofi, BMS, Vertex, and Novartis will make up the biggest drug launches next year.
By Sy Mukherjee • Dec. 15, 2014 -
Philly transit authority launches class action against Gilead over Sovaldi price
This is the first major payer lawsuit against Gilead over Sovaldi's exorbitant price.
By Nicole Gray • Dec. 12, 2014 -
Teva 2015 revenue forecast $1 billion lower than expected
Foreign exchange moves and anticipated generic competition for Copaxone led the generics giant to downgrade earnings forecasts for 2015.
By Nicole Gray • Dec. 12, 2014 -
Brave new world of digital pharma marketing has privacy advocates balking
Pharma is fine-tuning its online advertising by working with third-party vendors, which link patients, prescription-drug records, and Web ads.
By Nicole Gray • Dec. 11, 2014 -
'Audition' for a job? Pfizer gets creative in its hiring approach in Sweden
When Pfizer wanted to hire new employees for a large production site near Stockholm, Sweden, the company added an element of mystery and values assessment to the process.
By Nicole Gray • Dec. 11, 2014 -
Teva launches generic of Pfizer's arthritis med Celebrex in the US
The first generic celecoxib capsules will now be available in the U.S. in 50-, 100-, 200-, and 400-mg strengths.
By Nicole Gray • Dec. 11, 2014 -
Deep Dive
ICYMI: AARP and GPhA on what to do about generic drug price hikes
The AARP's Leigh Purvis and Ralph Neas of the Generic Pharmaceutical Association agree on the need for more generics competition. But they look at the problem through distinct lenses.
By Nicole Gray • Dec. 10, 2014 -
Big pharma meets medical marijuana? Dutch firm to build cannabinoid gum factory
Axim Biotechnologies currently has a non-psychotropic cannabinoid gum on the market as a nutraceutical, and is looking to move into the medical marijuana market.
By Nicole Gray • Dec. 5, 2014 -
Deep Dive
ICYMI: Are low-cost generic drugs a thing of the past?
There's a growing sense that the covenant between companies that manufacture and market generic drugs and the consumers who rely on them is broken.
By Nicole Gray • Dec. 3, 2014 -
Confirmed: GSK to chop 900 jobs, mostly in North Carolina, in massive reorg
About half of the jobs may be salvageable—but huge swaths of the R&D sector are slated for dismissal.
By Sy Mukherjee • Dec. 3, 2014 -
Why BMS is getting ready to slash up to 1,000 jobs in China
Amid corruption probes and market shifts in China, many pharma companies are retrenching. Sales reps will be feeling the brunt of BMS' layoffs.
By Nicole Gray • Dec. 2, 2014 -
Generic drug price hikes move Congress to consider consumer relief measures
Last year, prices for half of all generic drugs increased. In fact, they doubled for 10% of generics.
By Nicole Gray • Nov. 26, 2014 -
Takeda US CEO leaving after 22 years
As Takeda president and COO Christophe Weber seeks to overhaul management and offset losses from drugs going off patent, CEO Doug Cole has "decided to explore his options."
By Nicole Gray • Nov. 26, 2014 -
3 compounding pharmacies sue Express Scripts over blocked coverage
Express Scripts, the largest pharmacy benefits manager in the U.S., has been refusing to cover certain active ingredients used by compounding pharmacies.
By Nicole Gray • Nov. 25, 2014 -
Sacré bleu! Sovaldi to cost 38.8% less in France than in US
When it comes to procuring high-priced hep C meds for its citizens, France has savoir faire. A 12-week course of Gilead's Sovaldi will cost $51,373, the lowest price point in the EU.
By Nicole Gray • Nov. 21, 2014 -
Deep Dive
The 14 best-performing CEOs in biotech and pharma
From return on shareholders' investments to market capitalization, these 14 execs are among the best in the business.
By Sy Mukherjee • Nov. 21, 2014 -
Judge refuses to block Ranbaxy's generic competitors
Ranbaxy fought back after the FDA revoked tentative approvals of its generic versions of Nexium and Valcyte, suing the agency and seeking injunctions against competitors. So far, the strategy isn't panning out.
By Nicole Gray • Nov. 21, 2014 -
Sanofi can't shake its diabetes business blues—and investors aren't happy
Diabetes-related business comprises more than a fifth of Sanofi's revenues. So when the company projected flat sales through 2018 on Thursday, investors expressed their displeasure.
By Nicole Gray • Nov. 21, 2014 -
US hep C, cancer, diabetes med costs drive global drug tab past $1 trillion mark
A record year all around as total worldwide drug spending increases by 7% over 2013 levels.
By Sy Mukherjee • Nov. 20, 2014 -
These execs are on Sanofi's CEO short list
Sanofi is quietly compiling a list of candidates to replace sacked CEO Chris Veibacher. And executives from Takeda, Smith & Nephew, Bayer, and Novartis are reportedly on the short list.
By Nicole Gray • Nov. 20, 2014 -
Goodbye Philly, hello Boston: Shire moves US HQ, 500 jobs
Shire is leaving Chesterbrook, PA for Lexington, MA, seeking to benefit from the unique synergies that Massachusetts offers the biotech community.
By Nicole Gray • Nov. 20, 2014 -
Deep Dive
ICYMI: Inside Indian pharma's push to reform and modernize
The rapidly-growing Indian pharma industry faces numerous quality challenges but is working hard at reform, including by addressing regulatory inconsistency around fixed-dose combos.
By Nicole Gray • Nov. 19, 2014 -
Docs breathe sigh of relief as Actavis buyout ends Valeant-Allergan drama
"Finally, no more drama—and thank goodness Valeant didn't acquire Allergan!" That, in a nutshell, is how a group of surveyed ophthalmologists feels about Actavis' $66 billion acquisition of the Botox-maker.
By Nicole Gray • Nov. 18, 2014
Previous
